## This BinaxNOW COVID-19 Antigen Self Test has an expiration date beyond the date on the box.

According to the US Food and Drug Administration (FDA), the expiration date of this at-home COVID-19 test has been extended.

We are sending you this notice to update you that FDA has extended the expiration date on the self-test shipped to you. Please check the lot number on the box for the updated expiration date:

BinaxNOW COVID-19 Antigen Self Test EUA 210264/S003

Lot Number	Expiration Date on Box	Use Test By/Extended Expiration Date
169498	5/2/2022	8/2/2022
169797	5/2/2022	8/2/2022
169866	6/25/2022	9/25/2022
169889	6/25/2022	9/25/2022
172420	6/25/2022	9/25/2022
171771	9/18/2022	12/18/2022

Note: long exposure to high temperatures may impact the test performance. If your test has been left in a high temperature environment beyond the normal shipping time to be delivered to you, such as being left outside in the heat for several days, the FDA recommends considering using a different test.

## References:

At-Home COVID-19 Diagnostic Tests: Frequently Asked Questions <a href="https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/home-otc-covid-19-diagnostic-tests">https://www.fda.gov/media/155283/download</a>





January 7, 2022

Angela Drysdale VP, Regulatory Affairs Abbott Diagnostics Scarborough, Inc. 10 Southgate Road Scarborough, ME 04074

Re: EUA210264/S003

Trade/Device Name: BinaxNOW COVID-19 Antigen Self Test Dated: December 27, 2021 Received: December 27, 2021

Dear Ms. Drysdale:

This is to notify you that your request to; (1) update the shelf-life expiration date of the BinaxNOW COVID-19 Ag Card to 15 months at room temperature (28–30°C) based on the results of your ongoing stability studies, and (2) add use of an additional nitrocellulose membrane option for manufacturing, is granted. Upon review, we concur that the data and information submitted in EUA210264/S003 supports the requested updates for use with the BinaxNOW COVID-19 Antigen Self Test. FDA made some minor updates to the Healthcare Provider and Individual Fact Sheets to reflect more recent authorizations. By submitting this EUA revision for review by the Food and Drug Administration (FDA), you have complied with the Conditions of Authorization stated in the letter authorizing the emergency use of the BinaxNOW COVID-19 Antigen Self Test re-issued on November 8, 2021.

Sincerely yours,

Uwe Scherf, M.Sc., Ph.D.
Director, Division of Microbiology Devices
OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality
Center for Devices and Radiological Health